3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NIH
3
OTHER
1
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Breast Neoplasms
181
Lymphoma
97
Lymphoma, Large B-Cell, Diffuse
96
Precursor Cell Lymphoblastic Leukemia-Lymphoma
79
Sarcoma
69
Hodgkin Disease
54
Lymphoma, Non-Hodgkin
41
Triple Negative Breast Neoplasms
37
Burkitt Lymphoma
36
Lymphoma, Mantle-Cell
32
Leukemia
32
Lymphoma, Follicular
30
Multiple Myeloma
28
Carcinoma, Hepatocellular
28
Neoplasm Metastasis
23
Ovarian Neoplasms
21
Neoplasms
21
Lymphoma, Large-Cell, Anaplastic
18
Osteosarcoma
17
Lymphoma, B-Cell
17
Prostatic Neoplasms
16
Neuroblastoma
15
Lymphoma, T-Cell, Peripheral
15
Urinary Bladder Neoplasms
14
Recurrence
13
Lymphoma, Large-Cell, Immunoblastic
13
Inflammatory Breast Neoplasms
13
Immunoblastic Lymphadenopathy
13
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
11
Stomach Neoplasms
10
Interventions
Etoposide
4
Cyclophosphamide
3
Vincristine
2
Rituximab
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Melphalan
2
Cytarabine
2
Carmustine
2
efavirenz
1
VAP-cyclo protocol
1
Radiotherapy
1
Procarbazine
1
Ondansetron
1
O(6)-benzylguanine
1
Lomustine
1
Genes
1
Filgrastim
1
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
1
Doxorubicin
1
Aprepitant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma, AIDS-Related
×
Doxorubicin
×
Clear all
NCT00799136
2013-09-12
CATCH
Ontario Clinical Oncology Group (OCOG)
Phase 2
Completed
6 enrolled